By 2030, Offshore Formulation Development To Be Worth $60bn
A recent study predicts that the size of the global formulation development outsourcing market will increase from its value of $35.1 billion in 2022...
Usual Pharma Compliance Issues Noted In FDA Warning Letters
According to a study of the reasons behind warning letters sent by the US Food and Drug Administration Center for Drug Evaluation and Research and Center for...
US Gives Lynparza Priority Review If Paired With Abiraterone
Priority consideration has been given to AstraZeneca's supplemental new drug application for Lynparza (olaparib) when used in conjunction with abiraterone, prednisone, or prednisolone to...
NHS To Offer Variant-Busting Booster Before The Winters
The NHS has now laid out plans for the next stage of the COVID-19 vaccination effort, the biggest and most rapid vaccine drive in...
Evidence Shows Alzheimer Benefits From Genuv Cancer Drug
Mekinist (trametinib), which has been licenced by the FDA for the treatment of melanoma, was shown in a preclinical trial to have a neuroprotective...
Auvelity- A Possible Game Depression Treatment, Says Axsome
It is commonly known that there are insufficient therapy choices for major depressive disorder. Then the pandemic struck, increasing the number of patients with...
FDA Approves Zynteglo $2.8M Gene Treatment From Bluebird Bio
Gene therapy for blood disorders developed by Bluebird Bio has already left the nest in the US.
Zynteglo, sometimes known as betibeglogene autotemcel (beti-cel), was...
Subscribe Our Newsletter
White Papers
The Future of Digital Health
The pharmaceutical industry is acutely aware that the future of health and care, particularly in the United States, are trending toward a digital revolution....
Five Best Practices to Deliver Exceptional Multichannel Experiences
A one-size-fits-all customer journey no longer works. In the age of the consumer, the quality of the interaction is paramount. In this paper, we...
The Impact and Use of Social Media in Pharmacovigilance
Social media presents new channels and methods for biopharmaceutical companies to move away from traditional pharmacovigilance (PV) systems and safety reporting methods towards more...